Orthofix CEO awarded stock and option grants

Orthofix Medical Inc. President & CEO Massimo Calafiore received equity compensation awards on March 3, 2026.

Rhea-AI Filing Summary

Orthofix Medical Inc. President & CEO Massimo Calafiore received equity compensation awards on March 3, 2026. He was granted employee stock options for 273,279 shares at an exercise price of $0.00 and 115,119 shares of common stock in the form of restricted stock units.

The restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, Calafiore directly holds 332,356 shares of common stock, including previously reported restricted stock units, and 273,279 stock options.

Insider Trade Summary

Grant/Award: 388,398 shares

Grant/Award 2 txns

Insider Calafiore Massimo

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	273,279	$0.00	$0.00
Grant/Award	Common Stock	115,119	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 273,279 contracts (Direct); Common Stock — 332,356 shares (Direct)

Footnotes (3)

1. F1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date.
2. F2. Includes 135,369 previously reported restricted stock units.
3. F3. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Orthofix (OFIX) report for Massimo Calafiore?

Orthofix reported that President & CEO Massimo Calafiore received equity awards, including stock options and restricted stock units. These awards increase his direct ownership stake and align his compensation with the company’s future share performance through multi-year vesting conditions.

How many stock options were granted to the Orthofix (OFIX) CEO?

Massimo Calafiore was granted employee stock options covering 273,279 shares at an exercise price of $0.00. These options vest in three equal annual installments, with one-third of the options becoming exercisable on each of the first, second, and third anniversaries of the grant date.

What restricted stock unit award did Orthofix (OFIX) grant to its CEO?

Orthofix granted Massimo Calafiore 115,119 shares of common stock in the form of restricted stock units. These units vest in three equal annual tranches on the first, second, and third anniversaries of the grant date, subject to the company’s equity compensation plan terms.

How do the new equity awards affect the Orthofix (OFIX) CEO’s share holdings?

After the reported transactions, Massimo Calafiore directly holds 332,356 shares of Orthofix common stock, including previously reported restricted stock units. He also holds 273,279 stock options that will become exercisable over three years, further tying his compensation to the company’s share performance.

What is the vesting schedule for the Orthofix (OFIX) CEO’s new awards?

Both the restricted stock units and stock options granted to Massimo Calafiore vest over three years. One-third of each award vests on the first, second, and third anniversaries of the grant date, as approved by the board’s Compensation and Talent Development Committee.

Who approved the Orthofix (OFIX) CEO’s restricted stock unit grant?

The restricted stock unit grant to Massimo Calafiore was approved by Orthofix’s Compensation and Talent Development Committee of the Board of Directors. This committee administers the equity plan under which the restricted stock units were issued, including the multi-year vesting terms tied to the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 06:52 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calafiore Massimo

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		115,119(1)	A	$0	332,356(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$13.03	03/03/2026		A		273,279		(3)	03/03/2033	Common Stock	273,279	$0	273,279	D

Explanation of Responses:

1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date.

2. Includes 135,369 previously reported restricted stock units.

3. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.

	/s/ J. Andres Cedron, attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.